SNY

$44.60-0.74 (-1.63%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$44.60
Potential Upside
6.5%
Whystock Fair Value$47.49
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers-General

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$108.62B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.31
Beta
Defensive asset. Lower volatility than the S&P 500.
0.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
12.79%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.73

Recent News

Motley Fool
Mar 20, 2026

Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?

Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
BioPharma Dive
Mar 20, 2026

Earendil Labs, an AI-powered drugmaker, hauls in $787M

The hefty funding will support a U.S. and China-based startup that’s amassed a pipeline of nearly 20 drugs and formed two lucrative partnerships with Sanofi.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Mar 19, 2026

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading

European equities traded in the US as American depositary receipts were down sharply late Thursday m

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Mar 19, 2026

Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?

ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
24/7 Wall St.
Mar 18, 2026

20 Years on Wall Street Taught Me: Big Dividend Healthcare Stocks Never Go Out of Style

After a career spanning two decades at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing. My tenure at these premier Wall Street firms exposed me to fundamental analysis, credit evaluation, and risk management practices that directly translate into selecting high-quality dividend-paying companies. Having witnessed firsthand the 2008 ... 20 Years on Wall Street Taught Me: Big Dividend Healthcare Stocks Never Go Out of Style

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.